Bylvay® (odevixibat) data presented at aasld the liver meeting® 2022, demonstrating native liver survival in children across pfic types

Boston, nov. 07, 2022 (globe newswire) -- albireo pharma, inc. (nasdaq: albo), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, presented new data at the american association for the study of liver diseases (aasld) the liver meeting® 2022, being held november 4 – 8, 2022 in washington, d.c. across three oral presentations, including two late-breakers, and six posters, the company provided evidence of early, rapid, and sustained efficacy with bylvay (odevixibat) treatment in patients with progressive familial intrahepatic cholestasis (pfic) and alagille syndrome (algs).
ALBO Ratings Summary
ALBO Quant Ranking